Biomarkers For Alzheimer's, Parkinson's Disease To Be Developed By Industry Coalition Through First-Of-A-Kind Clinical Data Exchange
Executive Summary
Unable to defeat Alzheimer's Disease and Parkinson's Disease, companies have joined forces to come up with new research tools
You may also be interested in...
Searching For Surrogate Endpoints Requires Teamwork
Discussions between FDA and researchers during a workshop on the fatty liver conditions NAFLD/NASH clarified the status of potential surrogate endpoints for clinical trials, but indicated that much work remains to be done to ready the various options for use – and that will likely need to be a joint effort.
Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s
It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.
Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s
It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.